Ardelyx (ARDX) Announced New data for IBSRELA

Ardelyx, Inc. (NASDAQ:ARDX) is one of the Best American Penny Stocks to Buy According to AnalystsOn May 6, Ardelyx, Inc. (NASDAQ:ARDX) announced new data for IBSRELA at the Digestive Disease Week 2025 Conference.

IBSRELA is FDA-approved treatment for adults with irritable bowel syndrome with constipation. Management highlighted results from the IBS in America 2024 survey. The findings show that people with more severe IBS-C symptoms often face greater financial stress. This was measured using FACIT-COST and PROMIS-GI tools. Moreover, people with worse symptoms reported higher financial hardship.

Ardelyx (ARDX) Announced New data for IBSRELA

An aerial view of a pharmaceutical facility, showing the size and scale of the company’s operations.

The company also presented new data from a Phase 3 pediatric study, where IBSRELA was tested in patients aged 12 to under 18 with IBS-C. The results show that the medicine was well-tolerated, with the only side effect being diarrhea.

Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.